Option chain shows key data for Tenax Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Tenax Therapeutics.

Tenax Therapeutics (NASDAQ:TENX) Stock, Option Chain

Tenax Therapeutics

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Analysts

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CGON

SNDX

TENX

This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Penny Stocks

Small Cap

Movers

ACXP

AILE

BRSH

FLGC

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

NRXP

PLAG

RETO

SELX

SMFL

SNGX

SPEC

TANH

TIRX

TPET

ZAPP

Shares of  Alcoa Corporation (NYSE: AA) rose sharply in today’s pre-market trading after the company reported better-than-expected sales for its first quarter.

Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

ATXI

AUUD

BNED

CERO

GRPH

IMRN

MESO

OCUL

SVMH

TCBP

Shares of  Fangdd Network Group Ltd. (NASDAQ: DUO) rose sharply in today’s pre-market trading after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services sector.

Fangdd Network Group shares jumped 78.3% to $1.08 in pre-market trading

Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

Tenax Therapeutics Inc

TENX KEANE ACQUISITION RTS

TENX KEANE ACQUISITION UNITS 1 SHS & 1 RT &

TenX

Earnings

Press Releases

Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Management

Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Tenax Therapeutics Announces $25 Million Private Placement

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ATNM

AVTX

RDHL

Abpro Hldgs

ABVC BioPharma

Allakos

BioAtla

BioVie

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Curis

CEL-SCI

FibroGen

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Longeveron

Lisata Therapeutics

Mural Oncology

Ovid Therapeutics

Passage Bio

Pluri

Q32 Bio

Rallybio

Unity Biotechnology

Leerink Partners

Guggenheim

Roth MKM

Comments

Tenax Therapeutics

Tenax Therapeutics (TENX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga